Alcon completes acquisition of Ivantis, Hydrus microstent
Click Here to Manage Email Alerts
Alcon has completed its acquisition of Ivantis, gaining rights to the Hydrus microstent in the process, according to a press release.
“We believe this transaction will further strengthen our global surgical portfolio and help provide a platform for more growth in the glaucoma space,” David Endicott, CEO of Alcon, said in the release. “As we welcome Ivantis associates into Alcon, we look forward to introducing Hydrus microstent on a broader, global scale in the near future to help even more patients see brilliantly.”
The microstent is indicated to reduce IOP in mild to moderate open-angle glaucoma in procedures performed with cataract surgery in the U.S., with Alcon planning to pursue indications for the device as a stand-alone procedure, according to the release. The device is approved for stand-alone and combination procedures in the U.K., Canada, Australia, Singapore and Germany.
Read more about
Click Here to Manage Email Alerts